FDA Accepts Adolor/GSK Entereg Resubmission For Postoperative Ileus
This article was originally published in The Pink Sheet Daily
Executive Summary
Sponsors’ response to FDA clinical holds on the alvimopan program contain “substantially the same” information as the resubmitted NDA, Adolor tells “The Pink Sheet” DAILY.